

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/529,483	06/02/2000	ANDREAS MELZER	37418/DBP	8000
75	90 12/18/2003		EXAM	INER
D BRUCE PROUT			MANTIS MERCADER, ELENI M	
CHRISTIE PAR	RKER & HALE		ART UNIT	PAPER NUMBER
P O BOX 7068			AKI UNII	PAPER NUMBER
PASADENA, CA 91109-7068			3737	
			DATE MAILED: 12/18/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

-	Application No.	Applicant(s)			
	09/529,483	MELZER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Eleni Mantis Mercader	3737			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on 28	August 2003.				
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ Th	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
- 4)⊠ Claim(s) <u>1-43</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-43</u> is/are rejected.					
7) ☐ Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Exami	ner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. §§ 119 and 120					
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)⊠ All b)□ Some * c)□ None of:					
1. Certified copies of the priority documents have been received.					
<ul> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage</li> </ul>					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.					
<ul> <li>a)  The translation of the foreign language provisional application has been received.</li> <li>14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892)		(PTO-413) Paper No(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s		Patent Application (PTO-152)			
U.S. Patent and Trademark Office PTOL-326 (Rev. 11-03) Office	Action Summary	Part of Paper No. 15			

Application/Control Number: 09/529,483

Art Unit: 3737

## **DETAILED ACTION**

## Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1-43 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-71 of U.S. Patent No. 6,280,385. Although the conflicting claims are not identical, they are not patentably distinct from each other because they represent alternate variations and groupings. Furthermore, the broader scope of the current application which refers to the unfolding of a "medical device" including the LC circuit is inherently included in the narrower scope of US Patent No. 6,280,385 which applies to the unfolding of the stent including the LC circuit.

## Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 09/529,483

Art Unit: 3737

4. Claims 1-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fabian'095.

Fabian'095 teaches all the features of the current invention including localization of a surgical implement such as a sponge positioned within the patient by marking the sponge with an LC marker by an interrogation device (see col. 3, lines 66-68 and col. 4, lines 1-34). It is inherent that the sponge would expand with the absorption of blood and thereby unfold, inherently unfolding the LC marker.

Fabian'095 does not teach the use of an MRI apparatus as the interrogation device.

It would have been obvious to one skilled in the art at the time that the invention was made to have modified Fabian'095 and used MRI as an interrogation device as an alternate functional equivalent of inducing magnetic field into the LC circuit thereby enabling the same end result of its localization.

The arrangement of the inductors and capacitors is also an alternate functional equivalent providing obvious variations and combinations, which yield the same end result of localization of the surgical implement of interest.

Application/Control Number: 09/529,483

Art Unit: 3737

Page 4

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eleni Mantis Mercader whose telephone number is 703 308-0899. The examiner can normally be reached on Mon. - Fri., 8:00 a.m.-6:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dennis Ruhl can be reached on 703 308-2262. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0858.

> Eleni Mantis Mercader Primary Examiner

Elevillastinthorader

Art Unit 3737